퓨쳐켐

220100KOSDAQ의약품 제조업

49.0 / 100

Reference Date: 2026-06-10

Financial Score12.5 / 40

News Sentiment20.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 39.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

FutureChem develops radiopharmaceuticals by researching peptides similar to proteins specifically expressed in certain diseases, offering diagnostic and therapeutic drugs. Key products include FC303 for prostate cancer diagnosis and FC705 for treatment, leveraging theranostics technology for personalized medicine. The company utilizes the sCUBE® automated synthesis system to achieve GMP-level manufacturing standards.

Number of Employees

94people

Average Salary

53.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

4.68Industry Average 0.890.0Point

5.3x industry avg (risky)

ROE

-20.50Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

9.30Industry Average 12.435.0Point

Lower than industry avg (good)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.9% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲2.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.5% (declining, 3yr)

Detailed News Sentiment

13 totalPositive 12Neutral 0Negative 1Average Sentiment Score 81.9

Positive
퓨쳐켐, 전립선암 진단제 유럽 판권 반환…새 파트너 협상
퓨쳐켐이 전립선암 진단제 FC303의 유럽 판권을 회수하고 새로운 파트너와의 계약을 통해 시장 재진입을 모색함으로써 긍정적인 전망을 제공한다.
Negative
퓨쳐켐, 전립선암 진단 방사성의약품 'FC303' 기술이전 계약 해지
퓨쳐켐의 전립선암 진단 방사성의약품 기술이전 계약 해지로 인해 기업의 핵심 프로젝트 중단으로 인한 부정적 영향 예상.
Positive
퓨쳐켐, 400억원 유상증자 추진… 글로벌 임상·차세대 방사성의약품.....
퓨쳐켐의 400억원 유상증자로 차세대 방사성의약품 파이프라인 개발 가속화 및 임상 비용 확보가 이루어져 긍정적인 전망을 제공합니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 11,450Won52-week high 34,20052-week low 11,450

1-month return0.0Point

1m -39.90% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral투자판단관련주요경영사항 (전립선암 진단 방사성의약품 FC303 공동개발 기술이전 계약 해지 및 권리 반환)2026-06-04
Neutral주요사항보고서(유무상증자결정)2026-05-29
Neutral주권매매거래정지 (무상증자)2026-05-29
Neutral증권신고서(지분증권)2026-05-29
Neutral분기보고서 (2026.03)2026-05-14